title: Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.
abstract: OBJECTIVE
  To compare the susceptibility of respiratory cultures of Pseudomonas aeruginosa obtained from patients with cystic fibrosis to cefepime versus ceftazidime. The pattern of cumulative resistance of P aeruginosa to cefepime in patients who had received at least one treatment course of cefepime between two sputum cultures was also characterized.
  
  
  METHODS
  Prospective consecutive data collection.
  
  
  METHODS
  University-affiliated cystic fibrosis clinic and medical center.
  
  
  METHODS
  Eighty patients with cystic fibrosis who had at least one sputum culture positive for P aeruginosa with reported microbiologic susceptibilities to cefepime and ceftazidime.
  
  
  METHODS
  Patient data was collected and analyzed. Measurements and Main Results. Two hundred and thirty-one P aeruginosa isolates were collected over 6 months. A total of 16.4% and 8.7% of the isolates were nonsusceptible to cefepime and ceftazidime, respectively (p=0.01). In eight patients who had not received cefepime before the study period, nonsusceptibility was 11.8% and 27.2% before and after exposure to cefepime, respectively.
  
  
  CONCLUSIONS
  Susceptibility of P. aeruginosa isolates in patients with cystic fibrosis was lower with cefepime than with ceftazidime. Follow-up surveillance to determine changes in susceptibility of P aeruginosa isolates to cefepime is warranted.
authors.affiliation: Department of Pharmacy, University of Kentucky Chandler Medical Center, Lexington 40536-0293, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Robinson
authors.forename: R J
authors.initials: RJ
authors.lastname: Kuhn
authors.forename: J
authors.initials: J
authors.lastname: Craigmyle
authors.forename: M I
authors.initials: MI
authors.lastname: Anstead
authors.forename: J E
authors.initials: JE
authors.lastname: Kanga
mesh_terms: D000293:Adolescent; D000328:Adult; D000077723:Cefepime; D002442:Ceftazidime / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000382:microbiology*; D024881:Drug Resistance, Bacterial / Q000502:physiology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011446:Prospective Studies; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: D002511:Cephalosporins; D000077723:Cefepime; D002442:Ceftazidime